Carregant...
Siponimod: A Review in Secondary Progressive Multiple Sclerosis
Oral siponimod (Mayzent(®)), a next-generation, selective sphingosine 1-phosphate receptor (S1PR) 1 and 5 modulator, is approved in several countries for the treatment of secondary progressive multiple sclerosis (SPMS), with specific indications varying between individual countries. In the pivotal E...
Guardat en:
| Publicat a: | CNS Drugs |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer International Publishing
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7773609/ https://ncbi.nlm.nih.gov/pubmed/33108633 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40263-020-00771-z |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|